Deep brain stimulation works. The problem was always getting there.
Here is a fact that sounds like it should have been solved decades ago: we have known for years that carefully placed electrical pulses can quiet a Parkinsonian tremor, interrupt a seizure, or dull chronic pain. The therapy is real. The catch is the delivery. Traditional deep brain stimulation requires opening the skull and pushing an electrode into the brain - a serious operation that most eligible patients never get. NeuroBionics is a company built around a single, deceptively simple reframe: what if you didn't have to drill?
Founded out of more than a decade of research at MIT, NeuroBionics builds flexible, hair-thin bioelectronic fibers designed to reach neural targets through the body's own plumbing - the vasculature. The same highway a cardiologist uses to reach the heart, pointed at the nervous system. The lead device is called evStim, and the thesis behind it fits in one sentence: neuromodulation without open surgery.
It is a materials-science story dressed up as a medical-device story, which is the most honest way to describe it. You do not start with the app here. You start with the thread.
Figures compiled from company press releases and public profiles; seed total reflects the second close announced December 2025.
One fiber that speaks three languages
The nervous system does not communicate in a single channel. It uses electrical spikes, chemical messengers, and - if you are a neuroscientist with the right tools - light. Most neural interfaces pick one. NeuroBionics' fibers are built to handle all three at once, recording and stimulating across each. The company describes it as speaking the language of cells.
evStim
The clinical device. An endovascular neuromodulation platform that reaches deep brain and peripheral nerve targets through blood vessels rather than open surgery.
IO Fiber
The research tool. A multifunctional, research-grade fiber for neuroscience labs, integrating electrical, optical, and chemical recording and stimulation in a single strand.
Craniotomy vs. catheter
The clearest way to see the bet is to line up the two approaches. This is illustrative, not a clinical claim - but it captures why an endovascular route is worth chasing.
Conceptual comparison based on the company's stated rationale; not a substitute for clinical data.
Two PhDs and a department head walk out of a lab
NeuroBionics is a spinout in the most literal sense - the founding team carried a decade of fiber-drawing know-how out of an MIT lab and turned it into a manufacturing process for bioelectronic thread.
MJ Antonini
Biomedical engineer focused on neural device development; leads the company's push from validation toward first-in-human studies.
Nicki Driscoll
Expert in neural interfacing and carbon nanomaterials - the technical backbone of the fiber platform.
Polina Anikeeva
MIT materials-science professor and head of the Department of Materials Science & Engineering; scientific origin of the technology.
An oversubscribed seed, in two closes
Company founded, spinning MIT fiber and bioelectronics research into a startup based in Somerville, Massachusetts.
Closes an initial $5M seed led by Dolby Family Ventures to advance endovascular neuromodulation.
Signs a Galvorn carbon nanotube fiber offtake agreement with DexMat - securing the raw material for the platform.
Announces an oversubscribed $10M seed with a second close led by Future Ventures, alongside Vanedge Capital, Lionheart Ventures, Gaingels, and Opus 44.
The near-term regulatory play is telling. Rather than aiming straight at the brain, NeuroBionics is targeting short-term peripheral neuromodulation first, via the FDA's Class II de novo pathway - the faster, less glamorous route to actual patients. The brain comes later.
What this could actually do
For patients
A path to neuromodulation therapy - for Parkinson's, essential tremor, epilepsy, stroke, chronic pain, and depression - that could feel closer to a catheter procedure than to brain surgery.
For researchers
Multifunctional research fibers that let labs record and stimulate electrical, chemical, and optical activity in the same experiment, from a single strand.
For clinicians
A potential way to expand who can receive neuromodulation, by lowering the surgical bar that keeps most eligible patients out today.
For the field
A materials-first template for bioelectronic medicine, where the substrate - the fiber itself - is the strategy.
Five things worth knowing
01
The fibers are hair-thin, yet record and stimulate electrical, chemical, and optical signals simultaneously.
02
The endovascular route reaches the brain the way a catheter reaches the heart - through vessels, no skull opening.
03
Co-founder Polina Anikeeva also heads MIT's Department of Materials Science & Engineering.
04
The core material is Galvorn carbon nanotube thread, supplied by DexMat.
05
The first regulatory target is the peripheral nervous system - not the brain.
Go deeper
Interviews and explainers covering NeuroBionics' technology and its endovascular approach.
▶ Search video interviews & demos